Investigational Device · Provisional Patent Filed

Muscle Regeneration,
Delivered at the Point of Care

Myorenova is developing InjectaGel — a field-deployable injectable scaffold system designed to accelerate recovery from acute skeletal muscle injuries.

Explore the Science Get in Touch
3.6M+
Muscle strain injuries per year in the US
96.1%
Cell viability in vitro (ISO 10993)
<2 min
Field deployment time
The Problem

Muscle injuries have no repair solution

Acute skeletal muscle strains — common in military, sports, and occupational settings — affect millions annually. Current standard of care relies on rest, ice, compression, and elevation. There is no FDA-cleared biologic or device that actively promotes muscle tissue regeneration.

The result: prolonged recovery timelines, re-injury risk, and long-term functional deficits — especially in high-demand populations where rapid return to duty or play is critical.

"There is no FDA-cleared injectable treatment designed specifically to repair torn or damaged skeletal muscle at the point of injury."
6–8
Weeks of standard recovery
Even moderate Grade II strains sideline athletes and soldiers for weeks with no active regenerative intervention available.
30%
Re-injury rate within 12 months
Scar tissue formation during passive healing creates biomechanical weak points, significantly elevating re-injury risk.
$7B+
Annual economic burden (US)
Lost productivity, rehabilitation costs, and downstream surgical interventions make muscle injury a major healthcare burden.
0
FDA-cleared point-of-care muscle repair devices
The market gap is clear. No injectable scaffold designed for skeletal muscle regeneration has reached patients.
Our Technology

InjectaGel — A Proprietary Regenerative Scaffold System

InjectaGel is a field-deployable muscle regeneration system combining a proprietary bioactive hydrogel scaffold with a spring-driven dual-barrel autoinjector — engineered for use outside of clinical settings.

Component 01
Proprietary Bioactive Scaffold
A proprietary hydrogel scaffold providing tunable mechanical properties matched to native muscle tissue — supporting cell adhesion, proliferation, and organized regeneration.
Component 02
Body-Activated Gelation
Gelation is engineered to activate at body temperature without external energy sources — no UV light, heat, or power required. Purpose-built for field and sideline deployment.
Component 03
Spring-Driven Autoinjector
A mechanical-only, dual-barrel static-mixer delivery device achieving stoichiometrically precise mixing at ±2.8% accuracy. No electronics, no batteries — operable by non-clinical personnel.
Performance Metric
Verified Result
Status
Cell viability at 24 hours (ISO 10993)
96.1 ± 1.8%
PASS
Cell viability at 7 days
93.4 ± 2.7%
PASS
Scaffold gelation time
2 min 14 sec ± 18 sec
PASS
Young's modulus (target: native muscle range)
24.8 ± 3.4 kPa
PASS
4-week mechanical property retention
76.8 ± 4.9%
PASS
Injector deployment time
1 min 48 sec ± 12 sec
PASS
Sterilization modulus retention (UV screen)
93.1%
PASS
⚠ InjectaGel is an investigational device. It is not FDA cleared or approved, is not CE marked, and is not approved for human use outside authorized investigational frameworks. A provisional patent application has been filed. Proprietary formulation details are protected as trade secrets during the development period.
How It Works

From Injury to Recovery

InjectaGel is designed for rapid deployment at the point of care — no operating room required.

01 — Injury
Acute Muscle Strain
Patient sustains an acute skeletal muscle injury — on the field, at training, or in the field of duty. Immediate intervention is needed.
02 — Inject
Point-of-Care Delivery
A trained responder uses the spring-driven autoinjector to deliver InjectaGel directly into the injury site. No power source or clinical setting required.
03 — Gelation
Scaffold Forms In Situ
InjectaGel activates at body temperature, forming a stable bioactive scaffold within minutes — conforming to the injury site without external energy sources.
04 — Regeneration
Accelerated Recovery
The scaffold supports cell adhesion and organized muscle fiber regeneration — promoting faster, more complete recovery compared to passive healing alone.
Development Roadmap

Our Path to Market

A phased development plan toward FDA clearance and commercial launch in high-demand athletic and military settings.

Phase 1 — Current
2025–26
  • Prototype development
  • In vitro biocompatibility (ISO 10993)
  • Provisional patent filed
  • C-corp formation
  • Pre-seed fundraise initiated
Phase 2
2026–27
  • Utility patent filing
  • Pre-seed close
  • GMP-grade formulation
  • In vivo animal studies
  • FDA pre-submission meeting
Phase 3
2027–28
  • Seed round
  • 510(k) / De Novo submission
  • Pilot clinical study
  • Manufacturing scale-up
Phase 4
2029+
  • FDA clearance
  • Commercial launch
  • Series A
  • Military & sports markets
The Team

Built at Washington University in St. Louis

Myorenova was founded by a multidisciplinary team of biomedical engineers with deep expertise across materials science, mechanical design, and life sciences commercialization.

Myles Anderson
Co-Founder · CTO
Led hydrogel formulation development and system architecture. Biomedical Engineering, WashU.
Tyler Atsumi
Co-Founder · CEO & President
Responsible for corporate formation, intellectual property strategy, and commercial development. Biomedical Engineering, WashU.
Dominic Begora
Co-Founder · CFO
Led mechanical design and verification of the spring-driven dual-barrel autoinjector system. Biomedical Engineering, WashU.
Advisors & Partners
Sling Health Medtech Accelerator
Skandalaris Center WashU Entrepreneurship
Contact

Partner with Myorenova

We are actively seeking pre-seed investment, research partnerships, and clinical collaborators. Reach out to learn more about InjectaGel and our development roadmap.